Cervical Cancer / Uteri

Shaping your forecasting.

Welcome to theHub

Cervical Cancer / Uteri

Cervical cancer (ICD-10 code C53, uteri) is a type of cancer that occurs in the cells of the . Cervical cancer is generally preceded by Cervical Intraepithelial Neoplasia (CIN).

Cervical cancer is generally preceded by Cervical Intraepithelial Neoplasia (CIN). Nearly all cervical cancer cases (>90%) have been linked with HPV infection, with identification of 14 high-risk HPV (hrHPV) genotypes linked to cervical cancer. Typically, squamous cells lining the respond to exposure to HPV infection, causing them to replicate. The extent of abnormal growth (in the pre-cancerous phase) is the basis for CIN grading, from 1 to 3, where 3 represents disorganisation through the full extent of then epithelial layer. The following conditions are associated with the disease:

Infection with HPV genotypes 16 & 18
Extended use of contraceptives
Impaired immunity

Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumour, whether the cancer has spread and whether you would like to become pregnant someday.

Epidemiology Data

Data Available: Incidence Data

Data covers: Males and Females (where applicable) from 2010 to 2050.

Data is split into 5 year age ranges (0-4, 5-9 etc) from 0 to 100+ years, across multiple countries.

Additional sub filters of the data are available. Please see the below pop up box for more information.

Once purchased, the data will be provided in an embedded PowerBI document, in which the data can be filtered and viewed in a way which suits your needs. Raw data can also be downloaded. Below is an example embedded data set which can be filtered in a similar way.

Once the data set has been purchased, please refresh this page. The example data set will then be replaced with actual data.

Please contact us for further information regarding filtering of the data, viewing the data, data available, custom quotes, or anything else.

As well as incidence, data can be filtered by the following attributes (further filtering available is shown in brackets):

• Advanced metastatic treatment eligible
• Cachexia
• FIGO Stage Stage IA
• FIGO Stage Stage IB
• FIGO Stage
• Histopathology: Sub set (Adenocarcinoma, Adenosquamous Carcinoma, Carcinoma, Neoplasm, Other, Sarcoma, Small Cell Carcinoma, Squamous Cell Carcinoma)
• Locally advanced treatment eligible
• Lymph & Mets Distant Lymph Involvement
• Lymph & Mets Metastases
• Lymph & Mets No Lymph Involvement
• Lymph & Mets Regional Lymph Involvement
• Tumour Stage: Sub set (I, II, III, IV)

Further sub sets are available within the data, please contact us for more information.

Republic of Korea
Russian Federation
Saudi Arabia
South Africa
United Kingdom
United States of America

The more you buy, the more you save*

*discount added at checkout

For all your pharmaceutical
forecasting needs.

theHub is a portal of resources to help you create better forecasting. Courses, templates, software, data and working model examples to get you on the path to better forecasting. Sign up now to get access to a world of interactive content.

About J+D Forecasting.

At J+D it's our mission to simplify the complex nature of pharmaceutical forecasting to help support informed decision making for the future. We are dedicated to helping pharmaceutical and biotech companies use intelligent forecasting solutions to make strategic and operational investment decisions.

For decades, we have crafted bespoke pharmaceutical forecasting models, innovative software and interactive training solutions, each of which has been designed with client needs in mind, allowing businesses to create more intelligent and consistent insights.